Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis.
Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S. Lovren F, et al. Among authors: verma s. Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1377-84. doi: 10.1152/ajpheart.00331.2008. Epub 2008 Jul 25. Am J Physiol Heart Circ Physiol. 2008. PMID: 18660448 Free article.
Is There a Role for Colchicine in Acute Coronary Syndromes?
Nidorf SM, Verma S. Nidorf SM, et al. Among authors: verma s. J Am Heart Assoc. 2015 Aug 24;4(8):e002372. doi: 10.1161/JAHA.115.002372. J Am Heart Assoc. 2015. PMID: 26304942 Free PMC article. No abstract available.
The coronary heart team.
Yanagawa B, Puskas JD, Bhatt DL, Verma S. Yanagawa B, et al. Among authors: verma s. Curr Opin Cardiol. 2017 Sep;32(5):627-632. doi: 10.1097/HCO.0000000000000432. Curr Opin Cardiol. 2017. PMID: 28797011 Review.
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. Butler J, et al. Among authors: verma s. Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Eur J Heart Fail. 2017. PMID: 28836359 Free article. Review.
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Anker SD, et al. Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904 Free article.
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
Dewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Verma S, Jhund PS, McMurray JJV. Dewan P, et al. Among authors: verma s. Eur J Heart Fail. 2021 Apr;23(4):632-643. doi: 10.1002/ejhf.2083. Epub 2021 Jan 18. Eur J Heart Fail. 2021. PMID: 33368858 Free PMC article. Clinical Trial.
6,410 results